Icon

NEUTREXIN (nda020326)- (EQ 25MG BASE/VIAL,EQ 200MG BASE/VIAL)

TRIMETREXATE GLUCURONATE MEDIMMUNE ONCOLOGY
EQ 25MG BASE/VIAL,EQ 200MG BASE/VIAL
No No
2018-May-18 Expired
None None
None No
Neutrexin (trimetrexate glucuronate for injection) with concurrent leucovorin administration (leucovorin protection) is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprimsulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 25MG BASE/VIAL ** ** - - -
EQ 200MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.